{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-006960","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.841068+00:00","generated_at":"2026-06-22T20:45:53.943844+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aptose reports Q3 net loss $9.8M; tuspetinib completes dose escalation with CRs in FLT3+ AML","bullets":["Net loss $9.8M ($0.11/share) vs $11.3M ($0.13) in Q3 2021; cash $55.4M funds operations into Q1 2024.","Tuspetinib (HM43239) completes Phase 1/2 dose escalation; 120mg selected for single-agent expansion, 80mg with venetoclax.","FLT3-mutant patients with prior FLT3 inhibitor failure achieved complete remissions; responses also in FLT3 wildtype with TP53/NRAS.","Luxeptinib G3 formulation shows ~18-fold bioavailability improvement; continuous dosing of 50mg Q12h to start shortly.","USAN Council adopted generic name 'tuspetinib'; Aptose will use for all future references."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-006960","json":"https://secwatch.observer/filing/0001171843-22-006960.json","markdown":"https://secwatch.observer/filing/0001171843-22-006960.md","text":"https://secwatch.observer/filing/0001171843-22-006960.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184322006960/0001171843-22-006960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184322006960/f8k_110122.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T20:45:53.943844+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"53de5ceba1240da41d2d377c74bf70666a092b07","claim":"Aptose Biosciences Inc. reported the quarter ended September 30, 2022 results: revenue $ -, net income $9.8 million, EPS ($0.11 per share).","evidence_excerpt":"The net loss for the quarter ended September 30, 2022 was $9.8 million ($0.11 per share) compared with $11.3 million ($0.13 per share) for the quarter ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184322006960/0001171843-22-006960-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$ -"},{"label":"Net income","value":"$9.8 million"},{"label":"EPS","value":"($0.11 per share)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fe5c9e3efe764634eb0ae28418668dab1e59ef4c","claim":"Aptose Biosciences Inc. reported the nine months ended September 30, 2022 results: revenue $ -, net income $31.8 million, EPS $ (0.34).","evidence_excerpt":"Net loss for the nine-month period ended September 30, 2022 decreased by $9.2 million to $31.8 million, as compared to $41.0 million for the comparable period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184322006960/0001171843-22-006960-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2022"},{"label":"Revenue","value":"$ -"},{"label":"Net income","value":"$31.8 million"},{"label":"EPS","value":"$ (0.34)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}